<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467740</url>
  </required_header>
  <id_info>
    <org_study_id>1222.6</org_study_id>
    <secondary_id>EUDRACT 2006-004829-29</secondary_id>
    <nct_id>NCT00467740</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma</brief_title>
  <official_title>Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat® Inhaler in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
      inhalation solution delivered by the Respimat® inhaler for four weeks in patients with
      asthma. The selection of the optimum dose(s) will be based on bronchodilator efficacy (how
      well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount
      of the medication found in your blood).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 Response After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Pre-dose Morning PEFR After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline peak expiratory flow response (PEFR) was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 1 Week</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 2 Weeks</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Day 1</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 4</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 4</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 1 Week</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response After 4 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response At Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 1 Week</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 2 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response After 4 Weeks</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 6-12 h (AUC 6-12h) Response at Week 4</measure>
    <time_frame>1 hour (h) prior to dose on first day of randomized treatment (baseline) and 1h, 3h, 6h, 9h, 12h relative to dose at Week 4</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Evening PEFR After 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEFR Variability After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>PEFR variability represents the absolute difference between the highest morning PEFR value and the highest evening PEFR value of 1 day, divided by the arithmetic mean of these 2 PEFR values and expressed as a percent, weekly means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Weekly mean number of occasions of rescue therapy used per day (prn salbutamol [albuterol]) as assessed by the e-Diary (e-Diary incorporated in AM2+).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve From 0 to 3 Hours (AUC0-3)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
    <description>AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
    <description>Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Concentration (Tmax)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
    <description>tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
    <description>AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3 at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
    <description>AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=6 at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
    <description>AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=24 at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration at Steady State (Cmax,ss)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
    <description>Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)</measure>
    <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
    <description>tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score in Asthma Control Questionnaire After 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adequacy of asthma control was assessed using a scale of: 0=totally controlled, to 6=Severely uncontrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Testing: Average Change From Baseline of Potassium</measure>
    <time_frame>Baseline and 29 days</time_frame>
    <description>Laboratory testing: Average change from baseline of potassium measured on test-days. Pre−dose value on test day 1 is the baseline value.</description>
  </secondary_outcome>
  <enrollment type="Actual">296</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to
             participation in the trial, which includes medication washout and restrictions

          2. Male or female patients, 18 years of age or older

          3. Diagnosis of asthma (GINA)

          4. Pre-bronchodilator FEV1 greater than or equal to 60% predicted and &lt;90% predicted
             (ECSC);

          5. Increase in FEV1 greater than or equal to 12% and 200 ml 15 minutes after 400µg
             salbutamol (albuterol) at Visit 1

          6. Patient must have been taking Inhaled Corticosteroids for at least 12 weeks prior to
             screening, and must have been receiving a stable low/moderate dose for at least 6
             weeks prior to screening.

          7. Patients must be able to perform technically acceptable pulmonary function tests and
             PEF measurements, and must be able to maintain records (Patient Daily e-Diary) during
             the study period as required in the protocol

          8. Patients must be able to inhale medication in a competent manner from the Respimat®
             inhaler and from a metered dose inhaler (MDI).

        Exclusion Criteria:

          1. Patients with a smoking history of more than 10 pack years

          2. Patients with any of the following conditions: a diagnosis of thyrotoxicosis, a
             diagnosis of paroxysmal tachycardia (&gt;100 beats per minute), a marked baseline
             prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval &gt;450
             ms), a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)

          3. Patients with any of the following conditions: a history of myocardial infarction
             within 1 year of screening visit (Visit 1), a diagnosis of clinically relevant cardiac
             arrhythmia, a history of cor pulmonale, known active tuberculosis, a malignancy for
             which patient has undergone resection, radiation therapy or chemotherapy within last
             five years (patients with treated basal cell carcinoma are allowed), a history of
             life-threatening pulmonary obstruction, a history of cystic fibrosis, clinically
             evident bronchiectasis, a history of significant alcohol or drug abuse

          4. Patients who have undergone thoracotomy with pulmonary resection

          5. Patients who have taken an investigational drug within one month or six half lives
             (whichever is greater) prior to Screening Visit (Visit 1)

          6. Pregnant or nursing women

          7. Women of childbearing potential not using a highly effective method of birth control.
             Female patients will be considered to be of childbearing potential unless surgically
             sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at
             least 2 years

          8. Patients who have previously been randomized in this study or are currently
             participating in another study

          9. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.6.064 Arthur F. Gelb Medical Corporation, Lakewood</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.066 Allergy &amp; Asthma Medical Group and Rsrch Ctr, APC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.069 Allergy Associates Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.068 National Jewish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.067 Northeast Medical Research Associates, Inc</name>
      <address>
        <city>North Darthmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.061 Center for Human Genomics</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kileen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.071 Pulmonary Consultants</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bethune Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Briancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Pierre Cedex - La Réunion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.6.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Olo 2 mcg qd</title>
          <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P5">
          <title>Olo 20 mcg qd</title>
          <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B2">
          <title>Olo 2 mcg qd</title>
          <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B3">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B4">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B5">
          <title>Olo 20 mcg qd</title>
          <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="61"/>
            <count group_id="B6" value="296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.59" spread="14.11"/>
                    <measurement group_id="B2" value="45.36" spread="15.12"/>
                    <measurement group_id="B3" value="46.17" spread="12.96"/>
                    <measurement group_id="B4" value="46.25" spread="14.45"/>
                    <measurement group_id="B5" value="44.62" spread="12.95"/>
                    <measurement group_id="B6" value="45.23" spread="13.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.034"/>
                    <measurement group_id="O2" value="0.083" spread="0.032"/>
                    <measurement group_id="O3" value="0.090" spread="0.032"/>
                    <measurement group_id="O4" value="0.080" spread="0.032"/>
                    <measurement group_id="O5" value="0.150" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0754</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.167</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0571</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0906</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Pre-dose Morning PEFR After 4 Weeks</title>
        <description>Response was defined as change from baseline. Baseline peak expiratory flow response (PEFR) was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Pre-dose Morning PEFR After 4 Weeks</title>
          <description>Response was defined as change from baseline. Baseline peak expiratory flow response (PEFR) was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.18" spread="5.713"/>
                    <measurement group_id="O2" value="384.42" spread="5.377"/>
                    <measurement group_id="O3" value="396.06" spread="5.419"/>
                    <measurement group_id="O4" value="404.26" spread="5.465"/>
                    <measurement group_id="O5" value="411.13" spread="5.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0393</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.238</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.843</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.801</ci_lower_limit>
            <ci_upper_limit>31.675</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.878</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.875</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.379</ci_lower_limit>
            <ci_upper_limit>43.378</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>36.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.906</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.512</ci_lower_limit>
            <ci_upper_limit>51.633</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42.943</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.848</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.498</ci_lower_limit>
            <ci_upper_limit>58.389</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 1 Week</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 1 Week</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.033"/>
                    <measurement group_id="O2" value="0.060" spread="0.031"/>
                    <measurement group_id="O3" value="0.094" spread="0.032"/>
                    <measurement group_id="O4" value="0.106" spread="0.031"/>
                    <measurement group_id="O5" value="0.166" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1264</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0232</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0106</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.260</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.036"/>
                    <measurement group_id="O2" value="0.094" spread="0.034"/>
                    <measurement group_id="O3" value="0.080" spread="0.034"/>
                    <measurement group_id="O4" value="0.034" spread="0.034"/>
                    <measurement group_id="O5" value="0.131" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0329</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0666</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3738</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 1 Week</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 1 week</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 1 Week</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.036"/>
                    <measurement group_id="O2" value="0.053" spread="0.034"/>
                    <measurement group_id="O3" value="0.044" spread="0.034"/>
                    <measurement group_id="O4" value="0.070" spread="0.034"/>
                    <measurement group_id="O5" value="0.131" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2646</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3527</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1369</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.041"/>
                    <measurement group_id="O2" value="0.098" spread="0.039"/>
                    <measurement group_id="O3" value="0.069" spread="0.039"/>
                    <measurement group_id="O4" value="-0.002" spread="0.038"/>
                    <measurement group_id="O5" value="0.100" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0170</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0646</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6020</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0147</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.041"/>
                    <measurement group_id="O2" value="0.055" spread="0.039"/>
                    <measurement group_id="O3" value="0.076" spread="0.039"/>
                    <measurement group_id="O4" value="0.042" spread="0.039"/>
                    <measurement group_id="O5" value="0.166" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4902</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.068</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2832</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6516</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.081</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.037"/>
                    <measurement group_id="O2" value="0.269" spread="0.035"/>
                    <measurement group_id="O3" value="0.229" spread="0.035"/>
                    <measurement group_id="O4" value="0.190" spread="0.035"/>
                    <measurement group_id="O5" value="0.323" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.079</ci_lower_limit>
            <ci_upper_limit>0.277</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0512</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.001</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.331</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" spread="0.045"/>
                    <measurement group_id="O2" value="0.159" spread="0.042"/>
                    <measurement group_id="O3" value="0.154" spread="0.043"/>
                    <measurement group_id="O4" value="0.113" spread="0.043"/>
                    <measurement group_id="O5" value="0.267" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1811</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2118</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5504</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.312</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Day 1</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" spread="0.030"/>
                    <measurement group_id="O2" value="0.271" spread="0.028"/>
                    <measurement group_id="O3" value="0.275" spread="0.028"/>
                    <measurement group_id="O4" value="0.265" spread="0.028"/>
                    <measurement group_id="O5" value="0.383" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.260</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.291</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.214</ci_lower_limit>
            <ci_upper_limit>0.367</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.034"/>
                    <measurement group_id="O2" value="0.252" spread="0.032"/>
                    <measurement group_id="O3" value="0.258" spread="0.033"/>
                    <measurement group_id="O4" value="0.219" spread="0.032"/>
                    <measurement group_id="O5" value="0.325" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.279</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.067</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.263</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.174</ci_lower_limit>
            <ci_upper_limit>0.352</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.084" spread="0.038"/>
                    <measurement group_id="O2" value="0.298" spread="0.036"/>
                    <measurement group_id="O3" value="0.240" spread="0.036"/>
                    <measurement group_id="O4" value="0.172" spread="0.036"/>
                    <measurement group_id="O5" value="0.311" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.313</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0795</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.227</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.326</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 4</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 4</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 4</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" spread="0.037"/>
                    <measurement group_id="O2" value="0.271" spread="0.035"/>
                    <measurement group_id="O3" value="0.224" spread="0.035"/>
                    <measurement group_id="O4" value="0.192" spread="0.035"/>
                    <measurement group_id="O5" value="0.332" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.179</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0427</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.240</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.143</ci_lower_limit>
            <ci_upper_limit>0.336</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" spread="0.036"/>
                    <measurement group_id="O2" value="0.372" spread="0.034"/>
                    <measurement group_id="O3" value="0.378" spread="0.034"/>
                    <measurement group_id="O4" value="0.376" spread="0.034"/>
                    <measurement group_id="O5" value="0.499" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.263</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.296</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.202</ci_lower_limit>
            <ci_upper_limit>0.390</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 1 Week</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 1 Week</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.170" spread="0.036"/>
                    <measurement group_id="O2" value="0.343" spread="0.034"/>
                    <measurement group_id="O3" value="0.355" spread="0.034"/>
                    <measurement group_id="O4" value="0.308" spread="0.034"/>
                    <measurement group_id="O5" value="0.407" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.237</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.332</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.182" spread="0.041"/>
                    <measurement group_id="O2" value="0.386" spread="0.039"/>
                    <measurement group_id="O3" value="0.335" spread="0.039"/>
                    <measurement group_id="O4" value="0.261" spread="0.038"/>
                    <measurement group_id="O5" value="0.403" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.204</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.312</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1513</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.221</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.328</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.198" spread="0.040"/>
                    <measurement group_id="O2" value="0.363" spread="0.038"/>
                    <measurement group_id="O3" value="0.315" spread="0.038"/>
                    <measurement group_id="O4" value="0.279" spread="0.038"/>
                    <measurement group_id="O5" value="0.430" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.271</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0307</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1320</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.337</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response At Day 1</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response At Day 1</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.218" spread="0.041"/>
                    <measurement group_id="O2" value="0.297" spread="0.039"/>
                    <measurement group_id="O3" value="0.315" spread="0.039"/>
                    <measurement group_id="O4" value="0.315" spread="0.039"/>
                    <measurement group_id="O5" value="0.398" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1585</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0848</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0838</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.180</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.289</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 1 Week</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 1 Week</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.182" spread="0.044"/>
                    <measurement group_id="O2" value="0.281" spread="0.041"/>
                    <measurement group_id="O3" value="0.301" spread="0.042"/>
                    <measurement group_id="O4" value="0.259" spread="0.042"/>
                    <measurement group_id="O5" value="0.367" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0959</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0470</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1960</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.302</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 2 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 2 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.184" spread="0.047"/>
                    <measurement group_id="O2" value="0.327" spread="0.045"/>
                    <measurement group_id="O3" value="0.290" spread="0.045"/>
                    <measurement group_id="O4" value="0.234" spread="0.045"/>
                    <measurement group_id="O5" value="0.361" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1031</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4378</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" spread="0.051"/>
                    <measurement group_id="O2" value="0.274" spread="0.048"/>
                    <measurement group_id="O3" value="0.267" spread="0.048"/>
                    <measurement group_id="O4" value="0.235" spread="0.048"/>
                    <measurement group_id="O5" value="0.439" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2781</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3284</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.068</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6020</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.100</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.240</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>0.375</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 6-12 h (AUC 6-12h) Response at Week 4</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) prior to dose on first day of randomized treatment (baseline) and 1h, 3h, 6h, 9h, 12h relative to dose at Week 4</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 6-12 h (AUC 6-12h) Response at Week 4</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.051"/>
                    <measurement group_id="O2" value="0.107" spread="0.048"/>
                    <measurement group_id="O3" value="0.098" spread="0.049"/>
                    <measurement group_id="O4" value="0.092" spread="0.049"/>
                    <measurement group_id="O5" value="0.216" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4331</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5150</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.089</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5714</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.095</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Evening PEFR After 4 Weeks</title>
        <description>Response was defined as change from baseline. Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Evening PEFR After 4 Weeks</title>
          <description>Response was defined as change from baseline. Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.08" spread="5.585"/>
                    <measurement group_id="O2" value="407.05" spread="5.256"/>
                    <measurement group_id="O3" value="408.68" spread="5.297"/>
                    <measurement group_id="O4" value="420.88" spread="5.341"/>
                    <measurement group_id="O5" value="426.58" spread="5.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.970</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.665</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.883</ci_lower_limit>
            <ci_upper_limit>38.057</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.600</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.700</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.446</ci_lower_limit>
            <ci_upper_limit>39.754</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>36.806</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.727</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.598</ci_lower_limit>
            <ci_upper_limit>52.015</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42.505</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.675</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.399</ci_lower_limit>
            <ci_upper_limit>57.611</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEFR Variability After 4 Weeks</title>
        <description>PEFR variability represents the absolute difference between the highest morning PEFR value and the highest evening PEFR value of 1 day, divided by the arithmetic mean of these 2 PEFR values and expressed as a percent, weekly means.</description>
        <time_frame>4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>PEFR Variability After 4 Weeks</title>
          <description>PEFR variability represents the absolute difference between the highest morning PEFR value and the highest evening PEFR value of 1 day, divided by the arithmetic mean of these 2 PEFR values and expressed as a percent, weekly means.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>percentage of PEFR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.694" spread="0.780"/>
                    <measurement group_id="O2" value="10.575" spread="0.736"/>
                    <measurement group_id="O3" value="9.343" spread="0.739"/>
                    <measurement group_id="O4" value="8.649" spread="0.747"/>
                    <measurement group_id="O5" value="8.756" spread="0.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2898</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.194</ci_lower_limit>
            <ci_upper_limit>0.957</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.351</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.432</ci_lower_limit>
            <ci_upper_limit>-0.269</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.138</ci_lower_limit>
            <ci_upper_limit>-0.952</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.937</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.010</ci_lower_limit>
            <ci_upper_limit>-0.865</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</title>
        <description>Weekly mean number of occasions of rescue therapy used per day (prn salbutamol [albuterol]) as assessed by the e-Diary (e-Diary incorporated in AM2+).</description>
        <time_frame>4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</title>
          <description>Weekly mean number of occasions of rescue therapy used per day (prn salbutamol [albuterol]) as assessed by the e-Diary (e-Diary incorporated in AM2+).</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>Number of Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.449" spread="0.190"/>
                    <measurement group_id="O2" value="1.162" spread="0.179"/>
                    <measurement group_id="O3" value="0.923" spread="0.181"/>
                    <measurement group_id="O4" value="1.117" spread="0.182"/>
                    <measurement group_id="O5" value="0.856" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2645</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.287</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.257</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.793</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0423</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.526</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.258</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.034</ci_lower_limit>
            <ci_upper_limit>-0.018</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2008</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.332</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.259</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.842</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0218</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.593</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.257</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.098</ci_lower_limit>
            <ci_upper_limit>-0.087</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve From 0 to 3 Hours (AUC0-3)</title>
        <description>AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to 3 Hours (AUC0-3)</title>
          <description>AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram*hours/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;0;20;44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="11.8" spread="35.2"/>
                    <measurement group_id="O5" value="17.8" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;0;28;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="9.14" spread="48.6"/>
                    <measurement group_id="O5" value="20.3" spread="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax)</title>
        <description>Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <description>Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;21;44;58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.54" spread="48.4"/>
                    <measurement group_id="O4" value="4.63" spread="59.7"/>
                    <measurement group_id="O5" value="8.24" spread="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;38;54;57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.57" spread="82.1"/>
                    <measurement group_id="O4" value="5.00" spread="50.4"/>
                    <measurement group_id="O5" value="9.54" spread="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Concentration (Tmax)</title>
        <description>tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Concentration (Tmax)</title>
          <description>tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;21;44;58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.183" lower_limit="0.0830" upper_limit="2.97"/>
                    <measurement group_id="O4" value="0.234" lower_limit="0.0830" upper_limit="2.83"/>
                    <measurement group_id="O5" value="0.267" lower_limit="0.0670" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;38;54;57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.97" lower_limit="0.117" upper_limit="3.05"/>
                    <measurement group_id="O4" value="2.97" lower_limit="0.233" upper_limit="3.20"/>
                    <measurement group_id="O5" value="2.97" lower_limit="0.100" upper_limit="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)</title>
        <description>AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3 at steady state.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)</title>
          <description>AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3 at steady state.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram*hours/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;0;38;53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">No patients analyzed.</measurement>
                    <measurement group_id="O4" value="13.0" spread="42.7"/>
                    <measurement group_id="O5" value="25.5" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;38;44;54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="7.71" spread="62.2"/>
                    <measurement group_id="O4" value="9.04" spread="64.2"/>
                    <measurement group_id="O5" value="19.0" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)</title>
        <description>AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=6 at steady state.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)</title>
          <description>AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=6 at steady state.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram*hours/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;0;32;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">No patients analyzed.</measurement>
                    <measurement group_id="O4" value="25.3" spread="35.7"/>
                    <measurement group_id="O5" value="46.3" spread="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;21;23;33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.2" spread="58.2"/>
                    <measurement group_id="O4" value="21.3" spread="56.4"/>
                    <measurement group_id="O5" value="37.6" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)</title>
        <description>AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=24 at steady state.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)</title>
          <description>AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=24 at steady state.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram*hours/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="83.7" spread="30.3"/>
                    <measurement group_id="O5" value="147" spread="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="NA">No patients analyzed.</measurement>
                    <measurement group_id="O5" value="NA">No patients analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration at Steady State (Cmax,ss)</title>
        <description>Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration at Steady State (Cmax,ss)</title>
          <description>Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>Picogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol N=(0;0;39;45;56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.19" spread="35.0"/>
                    <measurement group_id="O4" value="5.09" spread="53.0"/>
                    <measurement group_id="O5" value="12.1" spread="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide N=(0;0;46;46;54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.16" spread="46.8"/>
                    <measurement group_id="O4" value="5.04" spread="57.4"/>
                    <measurement group_id="O5" value="9.19" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)</title>
        <description>tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
        <time_frame>30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration</time_frame>
        <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)</title>
          <description>tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.</description>
          <population>All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Olodaterol (N=0;0;39;45;56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.333" lower_limit="0.0830" upper_limit="2.92"/>
                    <measurement group_id="O4" value="0.333" lower_limit="0.0830" upper_limit="2.93"/>
                    <measurement group_id="O5" value="0.333" lower_limit="0.0830" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olodaterol glucuronide (N=0;0;46;46;54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.00" lower_limit="0.100" upper_limit="6.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="0.917" upper_limit="6.02"/>
                    <measurement group_id="O5" value="2.97" lower_limit="0.350" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score in Asthma Control Questionnaire After 4 Weeks</title>
        <description>Adequacy of asthma control was assessed using a scale of: 0=totally controlled, to 6=Severely uncontrolled.</description>
        <time_frame>4 weeks</time_frame>
        <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score in Asthma Control Questionnaire After 4 Weeks</title>
          <description>Adequacy of asthma control was assessed using a scale of: 0=totally controlled, to 6=Severely uncontrolled.</description>
          <population>Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.456" spread="0.089"/>
                    <measurement group_id="O2" value="1.314" spread="0.086"/>
                    <measurement group_id="O3" value="1.260" spread="0.086"/>
                    <measurement group_id="O4" value="1.129" spread="0.084"/>
                    <measurement group_id="O5" value="1.181" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2156</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.368</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0869</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.197</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.422</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0044</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.328</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.552</ci_lower_limit>
            <ci_upper_limit>-0.103</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.276</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.113</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.499</ci_lower_limit>
            <ci_upper_limit>-0.052</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination</title>
        <description>Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination</title>
          <description>Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Testing: Average Change From Baseline of Potassium</title>
        <description>Laboratory testing: Average change from baseline of potassium measured on test-days. Pre−dose value on test day 1 is the baseline value.</description>
        <time_frame>Baseline and 29 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Testing: Average Change From Baseline of Potassium</title>
          <description>Laboratory testing: Average change from baseline of potassium measured on test-days. Pre−dose value on test day 1 is the baseline value.</description>
          <population>Treated Set</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.94" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.93" upper_limit="1.02"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.95" upper_limit="1.05"/>
                    <measurement group_id="O4" value="0.99" lower_limit="0.96" upper_limit="1.03"/>
                    <measurement group_id="O5" value="0.97" lower_limit="0.92" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 2 mcg qd</title>
          <description>Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E5">
          <title>Olo 20 mcg qd</title>
          <description>Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

